Gen-Probe (GPRO) volatility elevated on uncertainty

Gen-Probe (Nasdaq: GPRO) is recently down 1.7% to $85.20 in pre-open trading, following a rally of 9.4% on May 18 after a WSJ story that said Thermo Fisher (NYSE: TMO), Novartis (NYSE: NVS), and Life Technologies (Nasdaq: LIFE) are interested in Gen-Probe. On April 28 the company said it was pursuing strategic alternatives and hired Morgan Stanley to seek a buyer for the company, Bloomberg reported. This morning Thermo Fisher announced the acquisition of Phadia. Madison Williams raised its price target to $90 from $76. June at the money call option implied volatility of 40 is above its six-month average of 25 according to Track Data.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Netflix (NFLX) April option implied volatility increases into quarter results
• Fifth Third Bancorp (FITB) April 34 puts active into quarter results and outlook
• Synovus Financial (SNV) call put ratio 1 call to 3.6 puts as share price down 6.8%